DG DISPATCH - ECFC: Third-Generation Cephalosporins Linked To Bacteria Infection In CF Patients
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




DG DISPATCH - ECFC: Third-Generation Cephalosporins Linked To Bacteria Infection In CF Patients

By Martin Goldman
Special to DG News

THE HAGUE, THE NETHERLANDS -- June 10, 1999 -- Third-generation cephalosporin antibiotics play a role in predisposing cystic fibrosis patients to Stenotrophomonas maltophilia colonisation and infection, according to new research presented at the European Cystic Fibrosis Congress (ECFC) in The Hague, The Netherlands.

The data was presented by Dr. Celine Piegay of the Service d’Epidemiologie et Hygiene Hospitaliere, Dijon, France. Her study reported that previous S. aureus colonisation and recent use of antibiotics also seem to be factors in predisposing cystic fibrosis patients to
S. maltophilia infection.

Thirty-three cystic fibrosis patients were enrolled in the retrospective, multi-centre, case control study which aimed to identify predisposing factors. Other predictive factors identified in this study were mean number of days in hospital (4.5 days for infected versus 1.4 for controls) and duration of oral antibiotic therapy (50.7 versus 22.4).

S. maltophilia is a ubiquitous organism, which has been increasingly identified as a significant pathogen in cystic fibrosis. When it occurs in addition to the more usual pathogens, such as Pseudomonas aeruginosa and Staphylococcus aureus, it seem to be directly related to the patients’ deterioration.

Dr. Piegay suggested that physicians should consider the presence of these predisposing factors before prescribing third-generation cephalosporins in their cystic fibrosis patients.

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities